1 reports of this reaction
4.2% of all Trelegy reports
#8 most reported adverse reaction
BLOOD POTASSIUM DECREASED is the #8 most commonly reported adverse reaction for Trelegy, manufactured by Aurobindo Pharma Limited. There are 1 FDA adverse event reports linking Trelegy to BLOOD POTASSIUM DECREASED. This represents approximately 4.2% of all 24 adverse event reports for this drug.
Patients taking Trelegy who experience blood potassium decreased should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
BLOOD POTASSIUM DECREASED is moderately reported among Trelegy users, representing a notable but not dominant share of adverse events.
In addition to blood potassium decreased, the following adverse reactions have been reported for Trelegy:
The following drugs have also been linked to blood potassium decreased in FDA adverse event reports:
BLOOD POTASSIUM DECREASED has been reported as an adverse event in 1 FDA reports for Trelegy. This does not prove causation, but indicates an association observed in post-market surveillance data.
BLOOD POTASSIUM DECREASED accounts for approximately 4.2% of all adverse event reports for Trelegy, making it a notable side effect.
If you experience blood potassium decreased while taking Trelegy, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.